And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

Professor Judith Smith, Suzie Bailey and Professor Sir Chris Ham explore why strong, well-trained NHS management is essential ...

As one provider moved from reactive paper-based management to proactive, tech-supported leadership, it has been focused on ...

Discover key insights from Trevi Therapeutics' Q3 2025 earnings call, including clinical progress, strong financials, and upcoming regulatory milestones.

Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.

Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics ...

Mangoceuticals, Inc. (NASDAQ: MGRX) ('Mangoceuticals” or the 'Company”) is issuing the following clarification regarding its ...

FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...

Digital transformation sits at the heart of the NHS Long Term Plan, promising a more connected, efficient, and ...

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...

P3 Health Partners Inc. (NASDAQ: PIII) Q3 2025 Earnings Call Transcript November 14, 2025 P3 Health Partners Inc. misses on ...

CORONA, CA – November 10, 2025 – PRESSADVANTAGE – Moment of Clarity has published a new resource, “TMS Therapy Success Rate ...